Glioblastoma multiform (GBM) is the most lethal form of brain cancer pigeonholed by a high
rate of reoccurrence and poor diagnosis. Among all treatment strategies available,
chemotherapy is considered the most common treatment entity at a clinical level.
Combination chemotherapy is believed to be a mainstay for the management of GBM
compared to monotherapy. As it augments the efficiency of the drugs and targets the tumor
site either in an additive or synergistic way. But, due to various limitations of drugs, explicitly …